In this protocol, patients meeting the clinical criteria for access to tocilizumab are selected based primarily on a hyperinflammatory presentation needing at least three of the following: elevated D‐dimer, rising CRP, ferritin > 1000 ng/mL, elevated LDH, in addition to confirmed SARS‐CoV‐2 with radiographic evidence of pneumonia and increasing oxygen requirement. Here, CRP is linked to pneumonia.